Real-World Studies Link Nonsteroidal Anti-inflammatory Drug Use to Improved Overall Lung Cancer Survival
Jason Roszik1,2, J Jack Lee3, Yi-Hung Wu3
1Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030.
Abstract:
Inflammation is a cancer hallmark. Nonsteroidal anti-inflammatory drugs (NSAIDs) improve overall survival (OS) in certain cancers. Real-world studies explored here if NSAIDs improve non-small cell lung cancer (NSCLC) OS. Analyses independently interrogated clinical databases from The University of Texas MD Anderson Cancer Center (MDACC cohort, 1987 to 2015; 33,162 NSCLCs and 3,033 NSAID users) and Georgetown-MedStar health system (Georgetown cohort, 2000 to 2019; 4,497 NSCLCs and 1,993 NSAID users). Structured and unstructured clinical data were extracted from electronic health records (EHRs) using natural language processing (NLP). Associations were made between NSAID use and NSCLC prognostic features (tobacco use, gender, race, and body mass index, BMI). NSAIDs were statistically-significantly (P < 0.0001) associated with increased NSCLC survival (5-year OS 29.7% for NSAID users versus 13.1% for non-users) in the MDACC cohort. NSAID users gained 11.6 months over nonusers in 5-year restricted mean survival time. Stratified analysis by stage, histopathology and multicovariable assessment substantiated benefits. NSAID users were pooled independent of NSAID type and by NSAID type. Landmark analysis excluded immortal time bias. Survival improvements (P < 0.0001) were confirmed in the Georgetown cohort. Thus, real-world NSAID usage was independently associated with increased NSCLC survival in the MDACC and Georgetown cohorts. Findings were confirmed by landmark analyses and NSAID type. The OS benefits persisted despite tobacco use and did not depend on gender, race, or BMI (MDACC cohort, P < 0.0001). These real-world findings could guide future NSAID lung cancer randomized trials.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) significantly improve overall survival (OS) for non-small cell lung cancer (NSCLC) patients. Real-world data confirm NSAID use is linked to better outcomes, regardless of patient characteristics.
Area of Science:
- Oncology
- Pharmacology
- Epidemiology
Background:
- Inflammation is a recognized hallmark of cancer.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) have demonstrated improved overall survival (OS) in specific cancer types.
- The impact of NSAIDs on non-small cell lung cancer (NSCLC) survival requires further real-world investigation.
Purpose of the Study:
- To evaluate the association between NSAID usage and OS in patients with NSCLC.
- To analyze real-world data from two independent healthcare systems to confirm findings.
- To explore if NSAID benefits in NSCLC are influenced by prognostic factors like tobacco use, gender, race, or BMI.
Main Methods:
- Retrospective analysis of clinical databases from MD Anderson Cancer Center (MDACC) and Georgetown-MedStar health system.
- Extraction of structured and unstructured data from electronic health records (EHRs) using natural language processing (NLP).
- Statistical analysis including survival assessments, stratified analyses by stage and histopathology, multivariable assessment, and landmark analyses to mitigate bias.
Main Results:
- NSAID use was statistically significantly associated with increased NSCLC survival in both the MDACC (5-year OS 29.7% vs. 13.1%) and Georgetown cohorts.
- NSAID users demonstrated a survival benefit of 11.6 months in restricted mean survival time.
- The survival benefits persisted across different stages, histopathology, and were independent of tobacco use, gender, race, or BMI.
Conclusions:
- Real-world NSAID usage is independently associated with significantly increased NSCLC survival.
- Findings were robust, confirmed across two independent cohorts and validated by rigorous analytical methods.
- These results support future randomized trials investigating NSAIDs for lung cancer treatment.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Related Concept Videos
Statistical Methods for Analyzing Epidemiological Data
Cancer Survival Analysis
Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
COPD: Management Using Bronchodilators and Corticosteroids
Cancer Prevention
Some...
